Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.

Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, Perfetto EM.

Am J Manag Care. 2002 Mar;8(3):231-40.

2.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

3.

Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.

Farahani P, Levine M, Gaebel K, Thabane L.

Can J Clin Pharmacol. 2005 Fall;12(3):e254-63. Epub 2005 Nov 7. Review.

PMID:
16278497
4.
5.

Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis.

Moreland LW.

Pharmacoeconomics. 2004;22(2 Suppl 1):39-53. Review. Erratum in: Pharmacoeconomics. 2004;22(8):547.

PMID:
15157003
6.

Etanercept: a review of its use in the management of rheumatoid arthritis.

Dhillon S, Lyseng-Williamson KA, Scott LJ.

Drugs. 2007;67(8):1211-41. Review. Erratum in: Drugs. 2007;67(13):1849.

PMID:
17521223
7.
8.

Economic and quality-of-life impact of rheumatoid arthritis.

Doyle JJ.

Manag Care. 2001 Jul;10(7 Suppl):15-8. Review.

9.
10.

[Immunomodulatory therapy improves quality of life with rheumatoid arthritis].

Graninger W.

Z Rheumatol. 2010 May;69(3):210-2. doi: 10.1007/s00393-009-0574-8. Review. German.

PMID:
20309699
11.

Quality of life and the outcome of established rheumatoid arthritis.

Kingsley G, Scott IC, Scott DL.

Best Pract Res Clin Rheumatol. 2011 Aug;25(4):585-606. doi: 10.1016/j.berh.2011.10.003. Review.

PMID:
22137926
12.

Rheumatoid arthritis. Outcome measures.

Paulus HE, Bulpitt KJ.

Rheum Dis Clin North Am. 1995 Aug;21(3):605-18. Review.

PMID:
8619091
13.

Patient-reported outcomes in rheumatoid arthritis.

Her M, Kavanaugh A.

Curr Opin Rheumatol. 2012 May;24(3):327-34. doi: 10.1097/BOR.0b013e3283521c64. Review.

PMID:
22410543
14.

Current treatments of rheumatoid arthritis: from the 'NinJa' registry.

Saeki Y, Matsui T, Saisho K, Tohma S.

Expert Rev Clin Immunol. 2012 Jul;8(5):455-65. doi: 10.1586/eci.12.35. Review.

PMID:
22882220
15.

Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity.

Strand V, Singh JA.

Drugs. 2010;70(2):121-45. doi: 10.2165/11531980-000000000-00000. Review.

PMID:
20108988
16.

The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis.

Matcham F, Scott IC, Rayner L, Hotopf M, Kingsley GH, Norton S, Scott DL, Steer S.

Semin Arthritis Rheum. 2014 Oct;44(2):123-30. doi: 10.1016/j.semarthrit.2014.05.001. Epub 2014 May 29. Review.

17.

Monitoring health outcomes among patients with arthritis using the SF-36 Health Survey: overview.

Keller SD, Majkut TC, Kosinski M, Ware JE Jr.

Med Care. 1999 May;37(5 Suppl):MS1-9. Review.

PMID:
10335739
18.

The burden of illness of rheumatoid arthritis.

Boonen A, Severens JL.

Clin Rheumatol. 2011 Mar;30 Suppl 1:S3-8. doi: 10.1007/s10067-010-1634-9. Epub 2011 Feb 26. Review.

PMID:
21359507
19.

Quality of life: what is it and can it be measured?

Strawbridge WJ.

Growth Horm IGF Res. 1998 Feb;8 Suppl A:59-62. Review.

PMID:
10993593

Supplemental Content

Support Center